On October 16, Buchang Pharmaceutical(603858) announced that its controlling subsidiary Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. and Suzhou WuXi AppTecNew Drug Development Co., Ltd. signed a "Technical Service Contract" with Luzhou Buchang Pharmaceutical Co., Ltd. The total contract amount is RMB 10.8 million, including 6% tax. Luzhou Buchang will pay the relevant fees in installments as agreed in the contract.

The collaboration aims to entrust WuXi AppTec to conduct pharmacokinetic and toxicology testing projects, which is expected to help expand the company's drug research and development capabilities and scope, and save clinical trial time and costs.

As of December 31, 2024, Luzhou Buchang’s total assets were 2.223 billion yuan, total liabilities were 2 billion yuan, and net assets were 223 million yuan. In 2024, it achieved operating income of 47,100 yuan and a net profit of -16.24 million yuan.

By June 30, 2025, total assets will rise to 2.34 billion yuan, total liabilities will be 2.121 billion yuan, and net assets will be 219 million yuan. In the first half of 2025, operating income will be 45 million yuan, and net profit will be -4.09 million yuan. This contract will not have an adverse impact on the company's financial condition and operating results.

By mid-2025, Stepan Pharmaceutical achieved revenue of 5.664 billion yuan and net profit attributable to shareholders of the parent company of 628 million yuan.

https://finance.eastmoney.com/a/202510163536138136.html